# Activation of NF-κB signaling in tissue-resident memory T cells promotes recurrent psoriasis in mice

**Authors:** Yukang Lin, Jiaying Chen, Han Du, Yuchao Chen, Zhaolin Liu, Xuejia Li, Yongdan Li, Feifei Qiu, Lingling Wen, Siyuan Xu, Huazhen Liu

PMC · DOI: 10.3389/fimmu.2025.1762269 · Frontiers in Immunology · 2026-02-09

## TL;DR

The study shows that activating NF-κB signaling in CD8+ tissue-resident memory T cells worsens psoriasis recurrence in mice.

## Contribution

The study identifies NF-κB signaling in CD8+ Trm cells as a novel driver of psoriasis recurrence.

## Key findings

- CD8+ Trm cells, not CD4+ Trm cells, are elevated in recurrent psoriatic mice.
- NF-κB signaling promotes Trm cell activation and psoriasis recurrence.
- NF-κB inhibition reduces dermatitis severity and Trm cell levels.

## Abstract

Recurrence triggered by immunological memory is a critical challenge in the treatment of psoriasis. Tissue-resident memory T (Trm) cells are the primary pacemakers in recurrent psoriasiform dermatitis following stimulation and infection by previous pathogens. However, the mechanisms underlying Trm cell activation remain unclear.

In this study, imiquimod-induced recurrent psoriatic mice were established to characterize the phenotypes of different Trm cell subsets. CD8+/CD4+ Tcm cell injection and NF-κB inhibitor or agonist treatment were then used to investigate the role and mechanisms of Trm cells in recurrent psoriasis. Finally, CD8+ T cells and keratinocyte co-culture systems were established to investigate the effects of activating NF-κB activation in Trm cells.

Mice displayed severe psoriatic dermatitis after repeated imiquimod treatment. The CD8+ Trm cells, but not CD4+ Trm cells, were elevated in the skin of recurrent psoriatic mice. Injection of CD8+ Tcm cells injection elicited more severe psoriatic symptoms than imiquimod treatment alone, indicating that CD8+ Trm cells are critical participants in psoriatic recurrence. Phosphorylation of NF-kB p65 (RELA), p-IKKa, p-RelB and NF-kB p100/p52 was enhanced in the skin of imiquimod-induced recurrent psoriatic mice. NF-κB inhibitor/agonist treatment significantly suppressed or restored the dermatitis severity and CD8+ Trm cell levels in recurrent psoriatic mice. Meanwhile, NF-κB inhibition also restored the expression of DLAT in Trm cells. Finally, NF-κB inhibitors directly suppressed Trm cell activation and inflammation of Trm cells in vitro.

Together, these findings suggest that canonical and non-canonical NF-κB signaling directly activates Trm cell differentiation, inhibits cellular cuproptosis, and promotes recurrent psoriasis.

## Linked entities

- **Genes:** NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970], DLAT (dihydrolipoamide S-acetyltransferase) [NCBI Gene 1737]
- **Chemicals:** imiquimod (PubChem CID 57469)
- **Diseases:** psoriasis (MONDO:0005083)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** DLAT (dihydrolipoamide S-acetyltransferase) [NCBI Gene 1737] {aka DLTA, E2, PBC, PDC-E2, PDCE2}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, Relb (Relb proto-oncogene, NFKB subunit) [NCBI Gene 19698] {aka shep}, Chuk (conserved helix-loop-helix ubiquitous kinase) [NCBI Gene 12675] {aka Chuk1, Fbx24, Fbxo24, IKBKA, IKK alpha, IKK1}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, Cxcl15 (C-X-C motif chemokine ligand 15) [NCBI Gene 20309] {aka Il8, Scyb15, lungkine, weche}, Rela (Rela proto-oncogene, NFKB subunit) [NCBI Gene 19697] {aka p65, p65 NF-kappa B, p65 NFkB}, Cxcl9 (C-X-C motif chemokine ligand 9) [NCBI Gene 17329] {aka CMK, Mig, MuMIG, Scyb9, crg-10}, Rel (Rel proto-oncogene, NFKB subunit) [NCBI Gene 19696] {aka c-Rel}, Sele (selectin, endothelial cell) [NCBI Gene 20339] {aka CD62E, E-selectin, ELAM-1, Elam, LECAM2}, Traf2 (TNF receptor-associated factor 2) [NCBI Gene 22030], ITGAE (integrin subunit alpha E) [NCBI Gene 3682] {aka CD103, HUMINAE}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, Il15 (interleukin 15) [NCBI Gene 16168] {aka IL-15}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Tpx2 (TPX2, microtubule-associated) [NCBI Gene 72119] {aka 2610005B21Rik, DIL2, REPP86, p100}, Dlat (dihydrolipoamide S-acetyltransferase) [NCBI Gene 235339] {aka 6332404G05Rik, DLTA, PDC-E2}, Cd69 (CD69 antigen) [NCBI Gene 12515] {aka 5830438K24Rik, AIM, VEA}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, Cxcr3 (C-X-C motif chemokine receptor 3) [NCBI Gene 12766] {aka Cd183, Cmkar3}, Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Selp (selectin, platelet) [NCBI Gene 20344] {aka CD62P, GMP-140, Grmp, LECAM3, PADGEM}, Itgae (integrin alpha E, epithelial-associated) [NCBI Gene 16407] {aka A530055J10, CD103, aM290, alpha-E1, alpha-M290}, Sell (selectin, lymphocyte) [NCBI Gene 20343] {aka CD62L, L-selectin, LAM-1, LECAM-1, LECAM1, Lnhr}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Nfkb2 (nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100) [NCBI Gene 18034] {aka NF-kappaB2, lyt, p49, p49/p100, p50B, p52}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}
- **Diseases:** infection (MESH:D007239), papillomatosis (MESH:D010212), epidermal hyperplasia (MESH:D006965), inflammation (MESH:D007249), HL (MESH:C538324), inflammatory dermatoses (MESH:D012871), HD (MESH:D006816), vitiligo (MESH:D014820), bleeding (MESH:D006470), dermatitis (MESH:D003872), acanthosis (MESH:D000052), psoriatic (MESH:D015535), psoriasiform dermatitis (OMIM:616834), Psoriasis (MESH:D011565), papulosquamous (MESH:D017444)
- **Chemicals:** CU-T12-9 (-), H&amp;E (MESH:D006371), hematoxylin (MESH:D006416), vaseline (MESH:D010577), CO2 (MESH:D002245), eosin (MESH:D004801), IMQ (MESH:D000077271), PVDF (MESH:C024865), formaldehyde (MESH:D005557), reactive oxygen species (MESH:D017382), paraffin (MESH:D010232), sphingosine-1-phosphate (MESH:C060506), TRIzol (MESH:C411644), SDS (MESH:D012967)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), CU-T12-9 — Gallus gallus (Chicken), Marek disease, Cancer cell line (CVCL_T554)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926151/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926151/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926151/full.md

---
Source: https://tomesphere.com/paper/PMC12926151